Zhiyi Biotech, a Guangzhou, China-based biotechnology company, raised $45M in Series B funding.
The round was led by Qingkong SinoKing Capital, SDIC Venture Capital, and KIP.
The company intends to use the funds to boost the clinical development of the its live biotherapeutic products (LBPs) pipelines.
Led by CEO Dr. Ye Wang, Zhiyi Biotech Zhiyi is a clinical-stage biotech leading in LBPs in China. It has built up a complete technical and industrial platform, covering from the isolation and identification of new functional strains to the development of innovative LBPs. Notably, the lead drug candidate in Zhiyi’s pipelines, SK08, is the first LBP developed on a unique bacterial strain Bacteroides Fragilis, and whose clinical progress is ahead of other LBPs in China. Phase II clinical trial of SK08 carried out in China to treat IBS-D is expected to be completed this year, and phase Ib/II trial of SK08 combined with PD-1 inhibitor for advance solid tumor has been initiated already. Meanwhile, several products are undergoing IND filing to both FDA and NMPA. More programs are expected to enter clinical stage in the foreseeing year. is advancing SK08, a strain-based LBP that entered clinical stage in China, the first LBP in oncology that was approved for clinical trial by NMPA. Owning two commercial-scale facilities, Zhiyi has established a complete platform system for strain selection, druggability study, CMC study, commercial production.